C07AB09 esmolol

CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Beta blocking agents, selective

健保收載品項 TFDA 在效許可證 1 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 1 張;以下列出 1 個品項。

健保收載品名:博立克注射劑100公絲

無外觀照
律平注射液 10 毫克/毫升

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 上心室心搏過速、手術中及手術後心搏過速、高血壓。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 esmolol hydrochloride in sodium chloride (商品名 Esmolol Hydrochloride / esmolol hydrochloride in sodium chloride) · 仿單更新 2023-10-09

1 INDICATIONS AND USAGE Esmolol hydrochloride in sodium chloride injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 ) 1.1 Supraventricular Tachycardia or Noncompensatory Sinus Tachycardia Esmolol hydrochloride in sodium chloride injection is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride in sodium chloride injection is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride in sodium chloride injection is intended for short-term use. 1.2 Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride in sodium chloride injection is indicated for the short-term treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride in sodium chloride injection to prevent such events is not recommended.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。